Diagnostic application of patent blue V in sentinel lymph node biopsy for breast cancer - Is it time for a change?

Abstract

Sentinel lymph node biopsy (SLNB) was introduced in the 1990s, as a minimally invasive procedure for staging the axilla with less morbidity to the traditional axillary lymph node dissection and is now standard management of the axilla in the early breast cancer. SLNB using the combined technique of blue dye and radioisotope is currently the recommended method for lymphatic mapping, and studies have shown high identification rates (IR) (>95%) and low false-negative rates (FNR) 5-10%. However, there are several reports raising awareness regarding patent blue V dye-induced peri-operative anaphylaxis. The main aim of this article is to highlight the emergence of patent blue dye as a new allergen and present evidence regarding the utility of alternative safer methods of evaluation of early breast cancer without compromising IR.

• Authors: Raghavan Vidya, Ruvinder Athwal, Aarnoud P Huissoon, Richard L Baretto, Mamidipudi Thirumala Krishna
• Journal: Indian journal of cancer (Indian J Cancer) 2019 Jul-Sep Vol. 56 Issue 3 Pg. 269-270 ISSN: 1998-4774 [Electronic] India
• PMID: 31389393 (Publication Type: Journal Article)

Chemical References

• Coloring Agents
• Rosaniline Dyes
• sulfan blue

Topics

• Breast Neoplasms (diagnosis, pathology, surgery)
• Coloring Agents (standards)
• False Negative Reactions
• Female
• Humans
• Prognosis
• Rosaniline Dyes (standards)
• Sentinel Lymph Node (pathology, surgery)
• Sentinel Lymph Node Biopsy (standards)